Following on from information provided to NICE by the company in November 2020, the appraisal of Pembrolizumab for gastric or gastroesophageal junction adenocarcinoma [ID1305] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 1305 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 08 November 2022 | Discontinued. Following on from information provided to NICE by the company in November 2020, the appraisal of Pembrolizumab for gastric or gastroesophageal junction adenocarcinoma [ID1305] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 17 December 2020 | The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of pembrolizumab for gastric or gastroesophageal junction adenocarcinoma. For information, the company have advised that they no longer intend to make a submission for this indication at this time because the technology will not be launched in the UK. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes. |
| 07 June 2019 | Suspended. As you will be aware the Department for Health and Social Care has NICE to carry out a Single Technology Appraisal of pembrolizumab within its marketing authorisation for treating gastric or gastroesophageal junction adenocarcinoma. Following on from advice received from the company, with regards to the latest results of the KEYNOTE-062 phase 3 study evaluating KEYTRUDA® (pembrolizumab) as monotherapy and in combination with chemotherapy for first-line treatment of patients with advanced gastric or gastroesophageal junction adenocarcinoma, NICE has decided to temporarily suspend this appraisal from its current work programme. As this appraisal has been referred, NICE will continue to monitor any development and will update interested parties if the situation changes. |
| 07 December 2018 | Following an update from the company, NICE has rescheduled the appraisal and it is expected to begin in mid-July 2019. |
| 18 July 2018 | As you will be aware, the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of pembrolizumab for gastric or gastroesophageal junction adenocarcinoma. Please note that the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early November 2018. |
| 31 January 2018 - 28 February 2018 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
| 24 April 2017 | In progress. DH referral received |
For further information on our processes and methods, please see our CHTE processes and methods manual